

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

LS513

RRID:CVCL_1386

Type: Cell Line

Proper Citation

RRID:CVCL_1386

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1386

Proper Citation: RRID:CVCL_1386

Description: Cell line LS513 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cecum adenocarcinoma

Defining Citation: [PMID:1389533](#), [PMID:1617643](#), [PMID:8895552](#), [PMID:9000147](#), [PMID:9000572](#), [PMID:11414198](#), [PMID:11526487](#), [PMID:12068308](#), [PMID:16418264](#), [PMID:16854228](#), [PMID:18258742](#), [PMID:20164919](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:22460905](#), [PMID:23272949](#), [PMID:23932154](#), [PMID:24755471](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:25984343](#), [PMID:27397505](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LS513

Synonyms: LS-513, LS 513

Cross References: CLO:CLO_0007407, CLO:CLO_0009969, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2134,

BioGRID_ORCS_Cell_line:563, BioSample:SAMN03472554, BioSample:SAMN10987976, cancercellines:CVCL_1386, CCRID:3101HUMTCHu237, Cell_Model_Passport:SIDM00677, ChEMBL-Cells:ChEMBL3308841, ChEMBL-Targets:ChEMBL2366311, CLS:300457, ColonAtlas:LS513, Cosmic:711275, Cosmic:724844, Cosmic:887230, Cosmic:907795, Cosmic:983740, Cosmic:1132570, Cosmic:1310942, Cosmic:1479582, Cosmic:1609478, Cosmic:1708410, Cosmic:1995492, Cosmic:2302000, Cosmic-CLP:907795, DepMap:ACH-000007, EGA:EGAS00001000978, GDSC:907795, GEO:GSM513914, GEO:GSM514301, GEO:GSM887281, GEO:GSM888356, GEO:GSM1006222, GEO:GSM1006223, GEO:GSM1006224, GEO:GSM1346849, GEO:GSM1374638, GEO:GSM1448141, GEO:GSM1670062, IARC_TP53:21480, KCLB:22134, LiGeA:CCLE_369, LINCS_LDP:LCL-1338, PharmacDB:LS513_864_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_1386, PubChem_Cell_line:CVCL_1386, Wikidata:Q54903070

ID: CVCL_1386

Record Creation Time: 20220427T220735+0000

Record Last Update: 20260920T004406+0000

Ratings and Alerts

No rating or validation information has been found for LS513.

No alerts have been found for LS513.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Thielen N, et al. (2026) High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. NPJ precision oncology, 10(1).

Zhuang X, et al. (2026) Receptor-ubiquitination-targeting antibody-drug conjugates for enhanced endocytosis and lysosomal delivery. Cell chemical biology, 33(4), 506.

He H, et al. (2026) L1TD1 promotes colorectal mucinous adenocarcinoma progression by enhancing ABCC3 mRNA stability. Oncogene, 45(12), 1071.

Vaeyens F, et al. (2026) Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs. International journal of cancer, 159(7), 1715.

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.

Satpathy S, et al. (2025) Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. *Cancer cell*, 43(9), 1731.

Baglamis S, et al. (2025) Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. *iScience*, 28(5), 112403.

Wang P, et al. (2025) Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. *Cancer research communications*, 5(5), 792.

Thielen N, et al. (2025) High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS G12D Mutated CRC. *bioRxiv : the preprint server for biology*.

Wang R, et al. (2025) Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. *Cell reports. Medicine*, 6(7), 102213.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.

Brubaker DK, et al. (2019) Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation. *Cell systems*, 9(3), 258.

Clarke PA, et al. (2016) Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. *eLife*, 5.